Irritable bowel syndrome affects approximately 10–15% of the European population,
although prevalence rates vary depending on the classification used and the country …

With this guideline, the World Gastroenterology Organisation (WGO) is aiming to guide
health providers in the best management of irritable bowel disease (IBS) through a concise …

These guidelines constitute an update of the previous “Recommendations on the
management of irritable bowel syndrome” issued in 2008. They have been developed by a …

Irritable bowel syndrome (IBS), a chronic gastrointestinal disorder, affects from 3–20% of the
US population, depending on sociocultural and comorbid factors. IBS is characterized by a …

Irritable bowel syndrome (IBS) is common in western Europe and North America, and many
aspects of its epidemiology, risk factors, and natural history have been described in these …

Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is
frequently seen in gastroenterological practice. Population-based studies have shown that …

Based on clinical studies, the Rome Criteria for the irritable bowel syndrome (IBS) were
developed by consensus. The criteria emphasize the presence of abdominal pain and the …

Background: IBS affects 5–11% of the population of most countries. Prevalence peaks in the
third and fourth decades, with a female predominance. Aim: To provide a guide for the …

Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal
disorder in primary and secondary care. It is characterised by abdominal discomfort, pain …

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal
disorders. A stepwise management approach is advocated for patients with IBS. For a …